Mizuho Maintains Buy on Amylyx Pharma, Lowers Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh has maintained a Buy rating on Amylyx Pharmaceuticals (NASDAQ:AMLX) but has reduced the price target from $46 to $27. This adjustment reflects a change in the expected future performance or valuation of the company.
December 21, 2023 | 3:42 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mizuho has maintained a Buy rating on Amylyx Pharmaceuticals but lowered the price target from $46 to $27, indicating a revision in the company's valuation.
The reduction in price target by a reputable analyst like Graig Suvannavejh could lead to a negative short-term sentiment among investors, as it suggests a lower valuation or tempered expectations for the company's future performance. While the Buy rating is maintained, the significant drop in the price target is likely to be the more impactful piece of news in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100